| 前收市價 | 2.2000 |
| 開市 | 2.2000 |
| 買盤 | 2.5000 |
| 賣出價 | 3.3000 |
| 拍板 | 31.00 |
| 到期日 | 2024-08-16 |
| 今日波幅 | 2.2000 - 2.2000 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 82 |
Insider MonkeyWhat Makes Corcept Therapeutics (CORT) a Good Investment Bet?
ClearBridge Investments, an investment management company, released its “ClearBridge Small Cap Value Strategy” first quarter 2024 investor letter. A copy of the letter can be downloaded here. The firm focuses on companies with strong balance sheets and attractive cash flows with compelling valuations rather than following market trends. The strategy outperformed the benchmark Russell 2000 Value […]
ZacksCorcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ReutersTeva sues Corcept over mifepristone 'monopoly' for rare disorder
Teva Pharmaceuticals sued rival drugmaker Corcept Therapeutics in federal court in San Francisco on Thursday, accusing it of monopolizing the market for mifepristone-based Korlym, used to treat a rare hormonal disorder called Cushing's syndrome. The lawsuit said Corcept and specialty pharmacy Optime Care, the sole distributor of Korlym, orchestrated “a multifaceted scheme to prolong Corcept’s monopoly by stifling competition from Teva at every turn.” Teva accused Corcept of "paying bribes and kickbacks" to physicians to keep them prescribing brand Korlym.
